Literature DB >> 7357490

The value of ultrasonic imaging and CT scanning in planning the radiotherapy for prostatic carcinoma.

D J Lee, S Leibel, R Shiels, R Sanders, S Siegelman, S Order.   

Abstract

Forty-four consecutive patients with potentially curable carcinoma of the prostate were localized with an Old Delft Simulator with the methods described by Bagshaw. The isocenter and the treatment portal were marked on the skin of the patient. Subsequently, the adequacy of the portal was checked by ultrasonography and/or CT scanning. Of 30 patients who underwent ultrasonography, five patients (17%) were found to have tumor extending beyond the initially simulated treatment portals. Using CT scanning, three of 22 patients were found to have tumor extending beyond the initially simulated portals. As a result, 1-2 cm were added to the initially simulated treatment portals for adequate coverage of the tumor volumes. Eight of our 44 patients underwent both studies and results were similar with ultrasonography and CT scanning. Only patients in the group presenting with clinical stage C disease had modifications of the initially simulated treatment portal. It is recommended that conventional simulation should be done first in order to establish the isocenter and treatment volume, which then should be confirmed by ultrasonography or CT scanning.

Entities:  

Mesh:

Year:  1980        PMID: 7357490     DOI: 10.1002/1097-0142(19800215)45:4<724::aid-cncr2820450419>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  [Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma].

Authors:  S Wachter; N Gerstner; K Dieckmann; M Stampfer; R Hawliczek; R Pötter
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

Review 2.  Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy.

Authors:  P F Schellhammer; G H Jordan; A M el-Mahdi
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.